📋 Tender Overview
Milestone underlines companys global leadership in sample preparationCompanys NGS assays also hit milestone of one million samples tested since 2015New kits and instruments will bolster QIAGENs position in most crucial area of molecular testingQIAGEN N.V. announced that the number of biological samples processed with consumables kits has passed the three billion mark a record that underlines its leadership in enabling molecular laboratories to gain valuable insights in research combatting diseases and forensics.This milestone particularly underscores QIAGENs standout position in sample preparation the most crucial stage of molecular testing at which DNA RNA or proteins are extracted from human samples. QIAGENs sample prep kits have become the gold standard in sample extraction and earned over 200000 references in academic studies. With more than 500 consumable kits and automated systems such as QIAsymphony QIAcube Connect QIAcube HT and EZ1 QIAGEN is the most trusted brand in sample preparation.Topping the three billion threshold truly demonstrates QIAGENs leadership in molecular testing said Thierry Bernard QIAGENs CEO. QIAGENs sample extraction kits can be found in practically every type of academic pharmaceutical forensic and clinical laboratory around the world. They are key to advancing scientific discoveries identifying diseases and many other applications that make improvements in life possible. Our constant innovation to make ever more challenging sample types easier to process will continue to strengthen our value in the market.QIAGEN has numerous new products in development among them are kits in the highly innovative area of liquid biopsy in which body fluids such as blood saliva or urine replace the need for biopsied tissue samples and the emerging field of microbiome research the study of the composition of microbial communities and its influence on disease onset progression or therapy response across a wide range of disorders. The company also plans to launch the EZ2 Connect for research human identification and molecular diagnostics applications as well as other new instruments to continue driving automation in the field of sample preparation.Sample technology is one of QIAGENs five pillars of growth alongside the QuantiFERON immune-response technology the NeuMoDx integrated PCR system the QIAstat-Dx syndromic testing solution and the QIAcuity digital PCR portfolio. Announced in August 2020 this focused long-term growth strategy is meant to establish or bolster QIAGEN as a top-three player in each of these fields and so continue the companys leadership in molecular analysis in both research and clinical testing applications.QIAGEN sample technologies are integrated with QIAGEN assays and bioinformatics solutions to enable customers to unlock valuable molecular insights or to seamlessly move from a raw biological sample to the final interpreted result as for example in next-generation sequencing NGS of DNA or RNA where QIAGEN has reached another major milestone.Since entering the market for universal NGS consumables in 2015 more than one million samples have been processed using our NGS panels said Thomas Schweins Senior Vice President of the Business Area Life Sciences of QIAGEN. This achievement is a strong testament to our commitment to serving customers from Sample to Insight as the vast majority of labs that use QIAGEN panels also use QIAGENs sample preparation technologies and bioinformatics solutions.NGS allows clinicians and researchers to quickly test hundreds of genes in a sample at the same time. In cancer treatment for example this allows doctors to efficiently identify genetic mutations that may be used to target the specific type of cancer. The growing number of these potentially important target mutations has given rise to personalized medicine in which test results guide treatment decisions.QIAGENs strong market position in this field is mainly driven by the companys ability to provide custom-made NGS assays. QIAGENs Enterprise Genomics Services Unit supports the worlds leading cancer-testing institutions in designing tailored cancer panels based on individual customer needs and ever-evolving scientific discoveries. It leverages QIAGENs industry-leading bioinformatics solutions including the QIAGEN Knowledge Base providing access to the worlds largest reservoir of biological and clinical findings with more than two million unique variants expertly selected from over 300000 scientific articles. More than 2 million NGS patient tests have been interpreted with QIAGEN Clinical Insight QCI the companys clinical decisions support platform.